Abstract
The association between treatment with danazol and hyperglucagonaemia was studied. Plasma glucagon concentrations were measured during an oral glucose tolerance test in seven women taking danazol and six healthy controls not taking danazol. Results showed that treatment with danazol is associated with severe hyperglucagonaemia, and in three patients glucagon concentrations reached the range suggestive of glucagonoma. It is important to recognise that this increasingly used drug may cause severe hyperglucagonaemia to prevent patients treated with danazol undergoing unnecessary investigations to localise glucagonoma.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Barbieri R. L., Ryan K. J. Hyperandrogenism, insulin resistance, and acanthosis nigricans syndrome: a common endocrinopathy with distinct pathophysiologic features. Am J Obstet Gynecol. 1983 Sep 1;147(1):90–101. doi: 10.1016/0002-9378(83)90091-1. [DOI] [PubMed] [Google Scholar]
- Mallinson C. N., Bloom S. R., Warin A. P., Salmon P. R., Cox B. A glucagonoma syndrome. Lancet. 1974 Jul 6;2(7871):1–5. doi: 10.1016/s0140-6736(74)91343-9. [DOI] [PubMed] [Google Scholar]
- Ward G. D. Dosage aspects of danazol therapy in the treatment of endometriosis. Postgrad Med J. 1979;55 (Suppl 5):7–9. [PMC free article] [PubMed] [Google Scholar]
- Wynn V. Metabolic effects of danazol. J Int Med Res. 1977;5 (Suppl 3):25–35. [PubMed] [Google Scholar]